Hologic 4Q Earnings Jump on Climbing Sales

Dow Jones

Nov 04, 2025

By Dean Seal

Hologic notched higher earnings and sales in its fiscal fourth quarter from robust demand across its product divisions.

The medical-technology company, which has agreed to be acquired by Blackstone and TPG, posted a profit of $187.3 million, or 83 cents a share, for the quarter ended Sept. 27, compared with $178.6 million, or 76 cents a share, in the same quarter a year earlier.

Stripping out one-time items, adjusted earnings were $1.13 a share. Analysts surveyed by FactSet had been expecting $1.10 a share.

Revenue rose 6.2% to $1.05 billion, ahead of analyst forecasts for $1.03 billion, according to FactSet.

Diagnostics revenue was up thanks to higher core U.S. molecular diagnostics sales, offsetting lower sales of Covid-19 assays and weaker sales in China. Its breast health division's revenue rose as well from strength in its interventional products. Surgical revenue climbed more than 10% from strong demand for its MyoSure and Fluent systems.

The company said last month that it would be bought for up to $18.3 billion in a deal that's expected to close in the first half of next year. It isn't providing guidance while the deal is pending.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

November 03, 2025 16:25 ET (21:25 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2580223063"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580223063\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580223063?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 05:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580223063","market":"nz","top_or_hot":-1,"title":"Hologic 4Q Earnings Jump on Climbing Sales","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Hologic notched higher earnings and sales in its fiscal fourth quarter from robust demand across its product divisions. \n</p>\n<p>\n  The medical-technology company, which has agreed to be acquired by <a href=\"https://laohu8.com/S/BX\">Blackstone</a> and TPG, posted a profit of $187.3 million, or 83 cents a share, for the quarter ended Sept. 27, compared with $178.6 million, or 76 cents a share, in the same quarter a year earlier. \n</p>\n<p>\n  Stripping out one-time items, adjusted earnings were $1.13 a share. Analysts surveyed by FactSet had been expecting $1.10 a share. \n</p>\n<p>\n  Revenue rose 6.2% to $1.05 billion, ahead of analyst forecasts for $1.03 billion, according to FactSet. \n</p>\n<p>\n  Diagnostics revenue was up thanks to higher core U.S. molecular diagnostics sales, offsetting lower sales of Covid-19 assays and weaker sales in China. Its breast health division's revenue rose as well from strength in its interventional products. Surgical revenue climbed more than 10% from strong demand for its MyoSure and Fluent systems. \n</p>\n<p>\n  The company said last month that it would be bought for up to $18.3 billion in a deal that's expected to close in the first half of next year. It isn't providing guidance while the deal is pending. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 03, 2025 16:25 ET (21:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hologic 4Q Earnings Jump on Climbing Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHologic 4Q Earnings Jump on Climbing Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-04 05:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Hologic notched higher earnings and sales in its fiscal fourth quarter from robust demand across its product divisions. \n</p>\n<p>\n  The medical-technology company, which has agreed to be acquired by <a href=\"https://laohu8.com/S/BX\">Blackstone</a> and TPG, posted a profit of $187.3 million, or 83 cents a share, for the quarter ended Sept. 27, compared with $178.6 million, or 76 cents a share, in the same quarter a year earlier. \n</p>\n<p>\n  Stripping out one-time items, adjusted earnings were $1.13 a share. Analysts surveyed by FactSet had been expecting $1.10 a share. \n</p>\n<p>\n  Revenue rose 6.2% to $1.05 billion, ahead of analyst forecasts for $1.03 billion, according to FactSet. \n</p>\n<p>\n  Diagnostics revenue was up thanks to higher core U.S. molecular diagnostics sales, offsetting lower sales of Covid-19 assays and weaker sales in China. Its breast health division's revenue rose as well from strength in its interventional products. Surgical revenue climbed more than 10% from strong demand for its MyoSure and Fluent systems. \n</p>\n<p>\n  The company said last month that it would be bought for up to $18.3 billion in a deal that's expected to close in the first half of next year. It isn't providing guidance while the deal is pending. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 03, 2025 16:25 ET (21:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HOLX","symbol_name":"豪洛捷","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2580223063","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580223063","pubTimestamp":1762205100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Hologic notched higher earnings and sales in its fiscal fourth quarter from robust demand across its product divisions.The medical-technology company, which has agreed to be acquired by Blackstone and TPG, posted a profit of $187.3 million, or 83 cents a share, for the quarter ended Sept. 27, compared with $178.6 million, or 76 cents a share, in the same quarter a year earlier.Stripping out one-time items, adjusted earnings were $1.13 a share. Analysts surveyed by FactSet had been expecting $1.10 a share.Revenue rose 6.2% to $1.05 billion, ahead of analyst forecasts for $1.03 billion, according to FactSet.Diagnostics revenue was up thanks to higher core U.S. molecular diagnostics sales, offsetting lower sales of Covid-19 assays and weaker sales in China. Its breast health division's revenue rose as well from strength in its interventional products. Surgical revenue climbed more than 10% from strong demand for its MyoSure and Fluent systems.The company said last month that it would be b","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"HOLX":"豪洛捷"},"translate_title":"Hologic第四季度盈利因销售额攀升而大幅增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOLX":1.5},"content_text":"By Dean Seal \n\n\n \n\n\n  Hologic notched higher earnings and sales in its fiscal fourth quarter from robust demand across its product divisions. \n\n\n  The medical-technology company, which has agreed to be acquired by Blackstone and TPG, posted a profit of $187.3 million, or 83 cents a share, for the quarter ended Sept. 27, compared with $178.6 million, or 76 cents a share, in the same quarter a year earlier. \n\n\n  Stripping out one-time items, adjusted earnings were $1.13 a share. Analysts surveyed by FactSet had been expecting $1.10 a share. \n\n\n  Revenue rose 6.2% to $1.05 billion, ahead of analyst forecasts for $1.03 billion, according to FactSet. \n\n\n  Diagnostics revenue was up thanks to higher core U.S. molecular diagnostics sales, offsetting lower sales of Covid-19 assays and weaker sales in China. Its breast health division's revenue rose as well from strength in its interventional products. Surgical revenue climbed more than 10% from strong demand for its MyoSure and Fluent systems. \n\n\n  The company said last month that it would be bought for up to $18.3 billion in a deal that's expected to close in the first half of next year. It isn't providing guidance while the deal is pending. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 03, 2025 16:25 ET (21:25 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}